Tocilizumab in Cardiac Transplantation

Status Active, not recruiting

Clinical Trial Summary

The purpose of this research study is to see if a study drug called Tocilizumab will, when given with standard anti-rejection medicines, lead to better heart transplantation outcomes at 1 year after the transplant. Specifically, the investigators will evaluate whether taking tocilizumab leads to less rejection, less development of unwanted antibodies, and better heart function.

Clinical Trial Description

This is a prospective, multi-center phase 2 clinical trial in which 200 primary heart transplant recipients will be randomized (1:1) to receive either tocilizumab (Actemra®) or placebo (normal saline) plus standard triple maintenance immunosuppression. Investigators will recruit primary heart transplant recipients from 14 participating centers. Subjects will be screened, consented, and enrolled while on the United Network for Organ Sharing (UNOS) wait list. When the recipient has received the transplant and is deemed hemodynamically stable, randomization will occur. Study duration: The study duration will be approximately 4 years. There will be a 36-month accrual period, and participants will be followed for a minimum 12-month, and a maximum 24 months after heart transplantation. *** IMPORTANT NOTICE: *** The National Institute of Allergy and Infectious Diseases does not recommend the discontinuation of immunosuppressive therapy for recipients of cell, organ, or tissue transplants outside of physician-directed, controlled clinical studies. Discontinuation of prescribed immunosuppressive therapy can result in serious health consequences and should only be performed in certain rare circumstances, upon the recommendation and with the guidance of your health care provider. ;

Study Design

Related Conditions & MeSH terms

Heart Transplant

Clinical Trial Details

NCT number	NCT03644667
Study type	Interventional
Source	National Institute of Allergy and Infectious Diseases (NIAID)
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	December 20, 2018
Completion date	April 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02964026` - Study of Clinical Outcomes Associated With the Pulmonary Artery Catheter (PAC) in Cardiac Surgery Patients	N/A
Active, not recruiting	`NCT05096299` - OCS Heart EXPAND + CAP Continued Follow-Up
Completed	`NCT02323321` - International EXPAND Heart Pivotal Trial	N/A
Not yet recruiting	`NCT05025774` - Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise
Recruiting	`NCT05933083` - MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation	N/A
Completed	`NCT03150095` - Health Coaching to Improve Self-Management in Thoracic Transplant Candidates	N/A
Active, not recruiting	`NCT02554578` - Impact of mHealth in Heart Transplant Management	N/A
Terminated	`NCT03346278` - Text Message Intervention to Improve Cardiac Rehab Participation	N/A
Active, not recruiting	`NCT05741723` - OCS DCD Heart + CAP Continued Follow-Up
Completed	`NCT03831048` - Donors After Circulatory Death Heart Trial	N/A
Completed	`NCT04615182` - Donor After Circulatory Death Heart CAP Trial	N/A
Completed	`NCT02597543` - Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction	Phase 4
Recruiting	`NCT05824364` - Exercise aNd hEArt Transplant	N/A
Enrolling by invitation	`NCT05390411` - Seeking Objectivity in Allocation of Advanced Heart Failure (SOCIAL HF) Therapies Trial	N/A
Recruiting	`NCT04770012` - AERIAL Trial: Antiplatelet Therapy in Heart Transplantation	Phase 3
Terminated	`NCT01769443` - Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantation	Phase 2
Completed	`NCT00466804` - Noninvasive Methods to Monitor Graft Survival in Heart Transplant Patients	N/A
Recruiting	`NCT06426173` - Effect of Resistance Training in Patients on the Waiting List for Heart Transplant	N/A
Not yet recruiting	`NCT05459181` - HeartCare Immuno-optimization in Cardiac Allografts (MOSAIC)	N/A
Terminated	`NCT01485757` - Prospective L-arginine Study	Phase 1